Under construction – not a live service
Sign in
Not yet recruitingNo phase

Effects of Epetôme on Gastrointestinal Function, Inflammation and Wellbeing in Adults With IBS-like Symptoms (EPEGUT)

Key facts

Who runs it
University of Roehampton
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
60 people, planned
Started
1 Nov 2026
Expected to end
20 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • EPEGUT
  • Placebo
Record updated
4 November 2026

Who can take part

Age
35 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Healthy adults, aged 35-50, with self-reported, persistent IBS-like gastrointestinal symptoms (e.g., abdominal pain or discomfort, bloating, altered bowel habits) at screening
  • Generally healthy, with no serious long-term medical conditions
  • Living in the UK
  • Able to read English and provide electronic informed consent
  • Willing and able to comply with study procedures, including dietary intervention and sample collection
  • Willing to provide stool, first-spot urine, saliva and blood samples at specified time points
  • No intentional dieting within the past month
  • Willing to keep their usual diet and not start other probiotic, prebiotic or fibre supplements during the study

Who cannot take part

  • Use of medications or special diets that significantly affect gut microbiota (e.g., chronic laxatives, immunosuppressants)
  • Formal diagnosis of IBS or any other gastrointestinal disease
  • Immunocompromised status or other serious chronic illness
  • Known allergies or intolerances to components of the study products (Epetome or placebo)
  • Use of antibiotics within the past 3 months
  • Regular use of probiotics or prebiotics within the past 4 weeks
  • Participation in another interventional clinical trial within the past 3 months

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 50 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Irritable bowel syndrome (IBS) is a common functional gastrointestinal condition characterised by symptoms including abdominal pain or discomfort, bloating, altered bowel habits and changes in digestive comfort. These symptoms can substantially affect quality of life, dietary behaviour, social functioning, and overall wellbeing. Although the underlying mechanisms are complex and multifactorial, growing evidence indicates that the gut microbiota and its interactions with the intestinal environment, immune system, gastrointestinal function, and gut-brain axis may play an important role in gastrointestinal health and symptom development. Prebiotics and probiotics have received increasing attention as nutritional strategies for supporting gut health. Prebiotics are substrates selectively utilised by beneficial microorganisms in the gut and can promote microbial growth and metabolic activity, including the production of short-chain fatty acids that contribute to intestinal barrier function, immune regulation, and colonic health. Probiotics are live microorganisms that, when administered in adequate amounts, may provide health benefits to the host. Selected probiotic strains have been investigated for their potential to support microbial balance, intestinal function, digestive comfort, and immune and inflammatory responses. However, responses to individual prebiotic or probiotic interventions can vary considerably between individuals, highlighting the potential value of complementary or combined nutritional approaches.

The 2 groups in the trial

  • (Epetōme® Synbiotic Dual Cap®)Existing treatment, for comparison

    A dietary supplement containing fructooligosaccharides (FOS), a prebiotic fibre, combined with probiotic microorganisms in capsule form.

    Treatment: EPEGUT

  • Placebo comparatorPlacebo, for comparison

    Matching placebo comparator

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
EPEGUT: Effects of Epetôme Supplementation on Gastrointestinal Function, Inflammatory Biomarkers and Wellbeing in Adults With IBS-like Symptoms
Fit questions
Built from NCT07916948, who can take part
Record updated
4 November 2026